GO
Loading...

Roche Holding AG

More

  • SHANGHAI, May 18- Chinese corruption charges against executives of British drugmaker GlaxoSmithKline Plc could be just the start of the pharmaceutical industry's problems in its biggest emerging drugs market, according to industry sources in China.

  • May 14- When the world's leading cancer doctors meet in Chicago next month, new treatments from Merck& Co, Bristol-Myers Squibb Co and Roche Holding AG that help the immune system fight disease are expected to capture much of the spotlight.

  • May 14- When the world's leading cancer doctors meet in Chicago next month, new treatments from Merck& Co, Bristol-Myers Squibb Co and Roche Holding AG that help the immune system fight disease are expected to capture much of the spotlight.

  • This year, at ASCO, all eyes are on pharma Wednesday, 14 May 2014 | 3:41 PM ET

    Some stocks moved after the bell after abstracts for the American Society of Clinical Oncology meeting dropped Wednesday.

  • LONDON, May 6- AstraZeneca Plc laid out its defence against Pfizer Inc's $106- billion takeover approach on Tuesday by predicting its sales would rise by three quarters over the next decade, although only after a short-term drop. "These are benefits that should fully accrue to AstraZeneca's shareholders."

  • LONDON, May 6- AstraZeneca Plc laid out its defence against Pfizer Inc's $106 billion takeover approach on Tuesday by predicting its revenues would rise 75 percent over the next decade, although only after a short-term drop. "These are benefits that should fully accrue to AstraZeneca's shareholders."

  • *India welcomes U.S. trade decision. NEW DELHI, May 1- India said on Thursday it would hold trade talks on intellectual property rights with the United States after its general election, buying time to address friction over drug patents until a new government is formed.

  • COLUMN-When the best offense is defensive stocks Wednesday, 23 Apr 2014 | 4:30 PM ET

    LONG BEACH, Calif., April 23- You've been on offense with your global stock portfolio for five years, running up the score in sectors like consumer discretionary and technology stocks that have outperformed the broad market. Jamie Doyle, co-manager of the Causeway Global Value Fund, is not ready to make a wholesale switch into defensive plays.

  • Why this biotech is rushing in as big pharma exits Wednesday, 16 Apr 2014 | 3:23 PM ET
    Barry Greene, Alnylam Pharmaceuticals

    This week the headline appeared to have some tough news for RNA companies, but Alnylam remains undeterred about the potential of its treatments.

  • Europe shares close lower; Ukraine concerns persist Tuesday, 15 Apr 2014 | 12:07 PM ET

    European shares closed lower on Tuesday, as Ukraine worries and fears about slowing demand in China weighed on stocks.

  • ZURICH, April 15- A strong uptake of new cancer medicines helped Roche to limit a decline in first-quarter sales and the Swiss company confirmed a forecast for higher earnings this year.

  • Roche looks to cancer drug to offset strong franc Tuesday, 15 Apr 2014 | 3:58 AM ET

    Swiss pharmaceuticals company Roche posted a rise in first-quarter sales but failed to meet market expectations as a strong Swiss franc hit results.

  • We are pleased with share price: Roche CEO     Tuesday, 15 Apr 2014 | 3:20 AM ET

    Severin Schwan, CEO of Roche, says he is "pleased" with the share price and results reported by the company.

  • *Q1 sales 11.496 bln Swiss francs vs 11.887 bln forecast. ZURICH, April 15- Adverse currency moves weighed on first-quarter sales at Roche Holding AG, which fell 1 percent, despite a healthy uptake of its new cancer medicines.

  • Flu drug stockpiles a waste of money: Report Thursday, 10 Apr 2014 | 6:27 AM ET

    The U.K. and U.S. governments spent millions stockpiling a flu drug that is no better than paracetamol, according to a new report.

  • April 8- Alkermes Plc said its experimental drug to treat the symptoms of schizophrenia met the main goal of reducing the severity of symptoms of the disease in a late-stage study. Alkermes success comes about a week after Australia- based Prana Biotechnology said its experimental drug to treat Alzheimer's disease failed a mid-stage study.

  • April 4- Halozyme Therapeutics Inc halted a mid-stage trial testing an advanced version of its flagship drug delivery technology in patients with pancreatic cancer, sending its shares tumbling 32 percent.

  • LONDON, April 2- GlaxoSmithKline Plc has stopped a high-profile clinical trial using a novel vaccine to fight lung cancer after deciding it will not be possible to find a sub-group of patients who might benefit.

  • March 31- Prana Biotechnology Ltd lost nearly three-quarters of its value after the company said its experimental drug to treat Alzheimer's disease failed a mid-stage study, raising doubts about the drug's future.

  • March 31- Curis Inc said the U.S. Food and Drug Administration allowed it to resume testing of its experimental cancer drug, lifting a November order halting enrolment in an early-stage trial. Curis acquired the license to develop and market the treatment from Genentech, a unit of the Roche Holding AG, for an upfront payment of $9.5 million in November 2012.